Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir interaction study with phenytoin or carbamazepine in healthy adults
NL-OMON37071Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telaprevir, phenytoin and carbamazepine in hepatitis C virus infection and epilepsy (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Safety and tolerability, Multiple-dose pharmacokinetics of phenytoin and telaprevir and 1 more. Started May 2012; status: active, not recruiting.
02
Drugs
telaprevirphenytoincarbamazepine
03
Conditions
hepatitis C virus infectionepilepsy
Beyond the preview
Go deeper on NL-OMON37071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37071.